HealthCCSng vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

HealthCCSng

by Nano-X AI

ElucidVivo A.3

by Elucid

AI Verdict

These tools are adjacent competitors, both leveraging AI for cardiovascular risk assessment from CT scans. HealthCCSng focuses on automatically detecting and quantifying coronary artery calcification from routine CT scans to identify patients at risk of coronary artery disease. In contrast, ElucidVivo A.3 provides a more detailed quantitative analysis of arterial plaque composition and stability, including calcifications, from CT angiography to aid in atherosclerosis patient stratification and treatment decisions.

Choose HealthCCSng if…

Choose HealthCCSng if your primary goal is to efficiently screen a broad patient population for early signs of coronary artery disease using existing, routine non-contrast chest CT scans. This tool is ideal for automatically identifying patients at risk by quantifying coronary artery calcification (CAC) and providing a calcium score without requiring dedicated cardiac imaging. It helps in proactive risk stratification and guiding further preventative care.

View HealthCCSng →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require a detailed, quantitative analysis of known arterial plaque composition and stability from CT angiography to optimize treatment decisions for patients with established atherosclerosis. This tool excels at identifying vulnerable plaque characteristics like Lipid-Rich Necrotic Core (LRNC) and deriving functional insights like FFRct, offering a deeper understanding beyond simple calcification scores. It is best suited for advanced patient stratification and guiding interventional strategies.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	HealthCCSng	ElucidVivo A.3
Pricing	Not publicly available	Unknown
Deployment	Cloud-based, integrates with PACS and EMR systems	Cloud and on-premise secure deployment.
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

HealthCCSng

Tool A emphasizes an automated workflow for results without human intervention and the ability to analyze routine non-contrast, non-ECG gated chest CT scans. This suggests a simpler, more streamlined user experience for broad screening and integration into existing clinical workflows, requiring less specialized input and user interaction.

Clinical Value

ElucidVivo A.3

While Tool A provides valuable coronary artery calcification (CAC) scoring, Tool B offers a more advanced and granular clinical insight by providing quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and fractional flow reserve (FFRct) derivation. Its validation against ground-truth histology further strengthens its claim to providing deeper, potentially more actionable information regarding plaque vulnerability and patient stratification for atherosclerosis.

Pricing & Value

Tie

Both tools explicitly state that their pricing is not publicly available and requires direct contact with the vendor. Without any comparative pricing information or detailed value propositions beyond their features, it is impossible to determine a winner in this dimension.

Enterprise Readiness

HealthCCSng

Tool A explicitly states HIPAA compliance and a cloud-based deployment model, along with seamless integration with PACS and EMR systems. While Tool B implies similar capabilities and FDA clearance, Tool A's explicit statements regarding compliance and cloud-native deployment provide greater transparency and confidence for enterprise adoption.

Innovation

ElucidVivo A.3

While Tool A innovates by automating CAC scoring from routine CT scans, broadening its applicability, Tool B demonstrates a deeper level of innovation. It provides quantitative analysis of arterial plaque composition and stability, including specific components like Lipid-Rich Necrotic Core, and offers FFRct derivation, all validated against ground-truth histology, which represents a more advanced approach to understanding plaque vulnerability.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offered sufficient specific information to compare the support and documentation offerings of HealthCCSng and ElucidVivo A.3. Therefore, it is not possible to determine a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	HealthCCSng	ElucidVivo A.3
Name	HealthCCSng	ElucidVivo A.3
Company	Nano-X AI	Elucid Bioimaging
Description	HealthCCSng is an FDA-cleared AI-powered solution that analyzes routine CT scans to automatically detect and quantify coronary artery calcification (CAC), identifying patients at risk of coronary artery disease.	ElucidVivo A.3 by Elucid Bioimaging is an FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.
Key Features	Analyzes non-contrast, non-ECG gated chest CT scans; Automatically detects and quantifies coronary artery calcification (CAC); Categorizes studies into 'zero', 'low', 'moderate', and 'severe' CAC categories; Generates a numerical calcium score; Provides visualization of calcified plaques within coronary arteries; Seamless integration with PACS and EMR systems; Automated workflow for results without human intervention; Customizable CAC category configuration	AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology
Primary Analysis Focus	Coronary Artery Calcification (CAC) detection and quantification from routine CT scans	Quantitative analysis of arterial plaque composition and stability from CT angiography

Videos

Demos, reviews, and walkthroughs featuring HealthCCSng and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of imaging input does each tool require?

HealthCCSng analyzes routine non-contrast, non-ECG gated chest CT scans to detect coronary artery calcification. In contrast, ElucidVivo A.3 performs quantitative analysis of arterial plaque composition and stability specifically from CT angiography.

What specific clinical insights does each tool provide?

HealthCCSng provides a numerical calcium score and categorizes studies into 'zero', 'low', 'moderate', and 'severe' CAC categories, along with visualization of calcified plaques. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, visualizes lesion-level plaque composition, and derives fractional flow reserve (FFRct).

What is the primary clinical application or patient population each tool targets?

HealthCCSng is designed to identify patients at risk of coronary artery disease by analyzing coronary artery calcification from routine CT scans. ElucidVivo A.3 assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics.

What is the key difference in the type of cardiovascular disease assessment offered by each tool?

HealthCCSng focuses on detecting and quantifying coronary artery calcification (CAC) from routine CT scans to assess a patient's risk of coronary artery disease. ElucidVivo A.3 provides a more detailed analysis of arterial plaque composition and stability, including quantification of Lipid-Rich Necrotic Core (LRNC) and calcifications, to aid in atherosclerosis patient stratification.

Has either tool been validated against a gold standard?

ElucidVivo A.3 has been validated on ground-truth histology for its quantitative analysis of arterial plaque composition. HealthCCSng is an FDA-cleared solution, and its authorization is supported by extensive clinical validation, including a standalone performance study and a fully crossed multi-reader, multi-case trial.